本帖最后由 老马 于 2013-3-13 13:43 编辑
* U8 c$ V) ~0 `+ l1 ?
5 @/ V; _" Y0 T- g1 [8 c健择(吉西他滨)+顺铂+阿瓦斯汀
7 W. c. O- I' ] e* { R Gemzar +Cisplatin + Avastin3 G3 H7 s6 P1 k* m
http://annonc.oxfordjournals.org/content/21/9/1804.full/ H5 q7 V8 w2 k F
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
4 n1 A4 m m1 d+ o, I) h; ^9 BPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. . n& y% ^9 G' q* A% g7 g
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
4 J( C' E+ x, s# J' o
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 839)
% @' [1 o& _; A& j) S- M
华为网盘附件:
/ [3 H F3 j) Z- E【华为网盘】ava.JPG; l/ ^6 R/ @: |/ |% z
|